Current Liabilities
Accrued Expenses
Eli Lilly Accrued Expenses increased by 20.8% to $2.38B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.4%, from $2.09B to $2.38B. Over 5 years (FY 2020 to FY 2025), Accrued Expenses shows an upward trend with a 19.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2015
Last reportedQ1 2026
How to read this metric
A steady balance is normal, but a rapid increase could indicate rising operational costs or delays in vendor invoicing.
Detailed definition
This represents liabilities for expenses that have been incurred but not yet invoiced or paid, such as utilities, profes...
Peer comparison
Standard current liability found in almost all corporate balance sheets.
Metric ID:
accrued_expensesHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $755.50M | $836.60M | $958.10M | $693.10M | $835.80M | $984.10M | $1.06B | $739.70M | $867.70M | $1.23B | $1.65B | $844.20M | $1.17B | $1.70B | $2.09B | $1.11B | $1.30B | $1.97B | $2.38B |
| QoQ Change | — | +10.7% | +14.5% | -27.7% | +20.6% | +17.7% | +7.7% | -30.2% | +17.3% | +42.1% | +33.8% | -48.8% | +38.4% | +45.8% | +22.9% | -46.8% | +17.0% | +50.9% | +20.8% |
| YoY Change | — | — | — | — | +10.6% | +17.6% | +10.6% | +6.7% | +3.8% | +25.3% | +55.7% | +14.1% | +34.6% | +38.1% | +26.9% | +31.9% | +11.5% | +15.4% | +13.4% |
Range$693.10M – $2.38B
CAGR+29.0%
Avg YoY Growth+21.1%
Median YoY Growth+15.4%
Current Streak3 quarters growth
Accrued Expenses at Other Companies
Frequently Asked Questions
- What is Eli Lilly's accrued expenses?
- Eli Lilly (LLY) reported accrued expenses of $2.38B in Q4 2025.
- How has Eli Lilly's accrued expenses changed year-over-year?
- Eli Lilly's accrued expenses increased by 13.4% year-over-year, from $2.09B to $2.38B.
- What is the long-term trend for Eli Lilly's accrued expenses?
- Over 5 years (2020 to 2025), Eli Lilly's accrued expenses has grown at a 19.0% compound annual growth rate (CAGR), from $997.20M to $2.38B.
- What does accrued expenses mean?
- Expenses the company has incurred but has not yet received a bill for or paid.